SAF 312

Drug Profile

SAF 312

Alternative Names: SAF312

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Non-opioid analgesics; Quinazolinones; Urologics
  • Mechanism of Action TRPV cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurogenic bladder; Postoperative pain

Most Recent Events

  • 14 Nov 2016 Novartis Pharmaceuticals plans a phase II trial for Postoperative Pain (Ocular pain) in USA (NCT02961062)
  • 22 Feb 2013 Novartis terminates a phase II trial in Neurogenic bladder in Belgium, Germany, Netherlands and Switzerland (NCT01598103)
  • 14 Oct 2009 Preclinical trials in Postoperative pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top